Researchers from Grey Wolf Therapeutics Ltd. presented the preclinical characterization of GRWD-0715, a selective ERAP1 inhibitor developed as a disease-modifying therapeutic approach aimed at preventing CD8+ T-cell activation and the subsequent tissue inflammation and damage associated with autoimmune conditions.
Hillstar Bio came out of stealth mode, announcing a $67 million series A financing round with investors including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S and Lifearc Ventures.
Hillstar Bio has successfully closed a $67 million series A financing round to support its development of next-generation precision immunology therapies for autoimmune diseases. The company’s approach selectively targets and depletes pathogenic immune cells with the potential to reset the immune system.
